SGX393 inhibits the CML mutant Bcr-Abl(T315I) and preempts in vitro resistance when combined with nilotinib or dasatinib

Imatinib inhibits Bcr-Abl, the oncogenic tyrosine kinase that causes chronic myeloid leukemia. The second-line inhibitors nilotinib and dasatinib are effective in patients with imatinib resistance resulting from Bcr-Abl kinase domain mutations. Bcr-Abl(T315I), however, is resistant to all Abl kinase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: O'Hare, Thomas, Eide, Christopher A., Tyner, Jeffrey W., Corbin, Amie S., Wong, Matthew J., Buchanan, Sean, Holme, Kevin, Jessen, Katayoun A., Tang, Crystal, Lewis, Hal A., Romero, Richard D., Burley, Stephen K., Deininger, Michael W.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2008
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2291110/
https://ncbi.nlm.nih.gov/pubmed/18367669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0800587105
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados